In the pharmaceutical industry, the focus has shifted towards exploring the potential of existing drugs in combating new challenges. GLP-1s, commonly known for their role in weight loss, have now piqued interest in alleviating long COVID symptoms. Tirzepatide, the active component in Zepbound, is set to undergo rigorous testing in a nationwide trial to determine its efficacy in treating long COVID.
GLP-1s like tirzepatide operate by interacting with receptors to regulate appetite, leading to weight loss. However, recent studies have revealed an additional benefit beyond shedding pounds – a notable anti-inflammatory effect on the body. This anti-inflammatory mechanism is now being explored as a potential solution for the persistent inflammation seen in long COVID patients.
Long COVID, affecting millions in the US, manifests in various symptoms such as coughing, fatigue, and brain fog. With the root cause still elusive, researchers speculate that tirzepatide’s anti-inflammatory properties could address the chronic inflammation associated with long COVID, offering hope for improved symptom management.
“Scripps researchers are actively enrolling participants nationwide to further investigate tirzepatide’s potential in combating long COVID,” said Dr. Eric Topol from the Scripps Research Translational Institute, emphasizing the drug’s potent anti-inflammatory properties.
Source: WIRED